The cerebral cavernous malformation 3 gene is necessary for senescence induction

Ana Guerrero,1,2 Cristina Iglesias,1 Selina Raguz,2,3 Ebel Floridia,1 Jesús Gil,2 Celia M. Pombo3 and Juan Zalvide1
1Department of Physiology, CIMUS, Instituto de Investigación Sanitaria IDIS, University of Santiago de Compostela, Santiago de Compostela A Coruña 15703, Spain
2Cell Proliferation Group, MRC Clinical Sciences Centre, Imperial College London, London W12 0NN, UK
3Quantitative Cell Biology, MRC Clinical Sciences Centre, Imperial College, London

Summary

Mutations in cerebral cavernous malformation 3 gene are known to result in development of vascular malformations and have recently been proposed to also give rise to meningiomas. We report in this study that lack of CCM3 unexpectedly impairs the senescence response of cells, and this is related to the inability of CCM3-deficient cells to induce the C/EBPβ transcription factor and implement the senescence-associated secretory phenotype. Induction of C/EBPβ and cytokines is also impaired in the absence of CCM3 in response to cytokines in nonsenescent cells, pointing to it being a primary defect and not secondary to impaired senescence. CCM3-deficient cells also have a defect in autophagy at late passages of culture, and this defect is also not dependent on impaired senescence, as it is evident in immortal cells after nutrient starvation. Further, these two defects may be related, as enforcing autophagy in CCM3-deficient late passage cells increases C/EBPβ cytokine expression. These results broaden our knowledge on the mechanisms by which CCM3 deficiency results in disease and open new avenues of research into both CCM3 and senescence biology.

Key words: autophagy; CEBPβ; PDCD10; SASP.

Introduction

Cellular senescence develops in response to a variety of stresses, including telomere attrition, unscheduled DNA replication, oxidative stress, suboptimal culture conditions, or the presence of an activated oncogene (in the latter case being called oncogene-induced senescence, OIS) (Hayflick, 1965; Kuilman et al., 2010). It was first described in cells in culture and is now widely accepted as an important antioncogenic mechanism in vivo (Braig et al., 2005; Collado et al., 2005; Michaloglou et al., 2005).

Some of the best known characteristics of senescent cells are those that are directly related to their growth arrest, such as the activation of p53 or the upregulation of the cyclin-dependent kinase inhibitors p16ink4a or p21CIP1 (Campisi & d’Adda di Fagagna, 2007). However, in the last few years, several other physiological changes have been shown to be important for the full implementation of the senescence program; among these are the secretion of a plethora of extracellular messengers, most prominently cytokines, by senescent cells (Krtolica et al., 2001; Coppé et al., 2006; Acosta et al., 2008; Kuilman et al., 2008; Kuilman & Peeper, 2009), and the stimulation of the process of macroautophagy (usually called simply autophagy) (Kurz et al., 2000; Young et al., 2009; Narita et al., 2011). Autophagy is necessary in this context for the efficient synthesis and secretion of extracellular messengers (Young et al., 2009), and once established, the synthesis and secretion of cytokines can be self-sustained by a positive feedback loop involving the transcription factors NFκB and C/EBPβ (Acosta et al., 2008).

Mutations in the CCM3/PDCD10 gene (CCM3 from here on) predispose to cerebral cavernous malformations (CCM, OMIM #116860), a common type of vascular malformation which develop almost exclusively in the central nervous system (Rigamonti et al., 1988). Its product is an adaptor protein that binds to the germinal center kinase III (GCKIII) family of protein kinases (composed of Mst3/STK24, Mst4/MAK, and SOK1/YSK1/STK25) through its N-terminal domain (Ma et al., 2007; Voss et al., 2009; Fidalgo et al., 2010; Zalvide et al., 2013), and to other proteins through its C-terminal end (Voss et al., 2007; Goudreault et al., 2008; Fidalgo et al., 2010; Li et al., 2011). Several functions have been proposed for CCM3, including modulation of cell death, especially after oxidative stress (Chen et al., 2009; Schleider et al., 2010; Fidalgo et al., 2012; Zhang et al., 2012), regulation of transmembrane signaling and cell growth (Ma et al., 2007; Kleaveland et al., 2009; He et al., 2010; Lin et al., 2010), and playing a role in membrane trafficking, Golgi apparatus biogenesis, cell migration, and regulated secretion (Fidalgo et al., 2010; Zhang et al., 2013; Louvi et al., 2014).

Recently, patients carrying heterozygous CCM3 gene mutations have been shown to be at high risk of developing meningiomas in which the wild-type allele of CCM3 is mutated (Labaigue et al., 2009; Riant et al., 2013), which hints to a possible role of CCM3 as a tumor suppressor, although no mechanism for such an effect has been proposed. Here, we show that cells deficient in CCM3 do not enter senescence after replicative stress or oncogene induction. Lack of CCM3 results in impaired expression of cytokines and their regulator C/EBPβ, both in senescence and in response to cytokines. Moreover, CCM3-deficient cells do not increase autophagy at late passages of culture or after nutrient starvation.

Results

To study the biology of the cavernous malformation susceptibility gene CCM3, we depleted the CCM3 protein in primary endothelial cells by lentiviral transduction of CCM3 small hairpin RNAs. Two of the shRNAs—shCCM3#1 and shCCM3#2—we used gave a good downregulation of CCM3 (Fig. 1A). As expected for primary cells, those infected with a control shRNA stopped their proliferation when they reached between 6 and 12 population doublings, and showed the typical morphology of senescent cells. Surprisingly, cells with a downregulated CCM3 continued to divide when they reached the same number of doublings. Cells...
inhibitors p21cip1 or p16ink4a (Fig. S1D,E, Supporting information). They were genic, but did not form foci when allowed to grow to confluence (Fig. S1B, Supporting information). In contrast, cells infected with the less effective shCCM3#2 shRNA had an intermediate phenotype, proliferating longer than the control cells but ultimately ceasing their division (Fig. 1B). Significantly, the proliferation during the first 3 divisions of the cells was undistinguishable in cells with different levels of CCM3 depletion and not to nonspecific effects of the shRNAs, we reexpressed CCM3 with retroviral transduction. The shCCM3 #1 shRNA targets the 3’ UTR of the CCM3 mRNA, and therefore, it does not have any effect on a construct with the coding region of CCM3. CCM3 transduction could recover CCM3 protein levels partially, and this was enough to increase significantly the number of positive cells for SA-βGal activity (Fig. 1D), indicating that senescence was being rescued.

To know how widespread the relation of CCM3 to senescence was, we depleted this gene from IMR90 fibroblasts using a CCM3 shRNA unrelated to those previously used (Fig. S2A, Supporting information). CCM3-depleted fibroblasts did not enter senescence at the same passage as control cells (Fig. S2B, Supporting information), although they showed signs of senescence three passages later (not shown), suggesting CCM3 only delays senescence in this model.

We hypothesized that if CCM3 was specifically required for replicative senescence, its expression might be increased during the process. However, CCM3 mRNA levels did not vary significantly as IMR90 cells accumulated population doublings (Fig. S2C, Supporting information), suggesting CCM3 is activated, it is through a mechanism different than mRNA expression.

We then studied the effect of CCM3 in senescence in a well-known model of senescence induction: IMR90 cells transduced with an oncogenic H-ras switchable with the estrogen analog 4-hydroxytamoxifen (4-OHT). When CCM3 was inhibited in these cells (Fig. 2A), 4-OHT could still increase the number of γH2AX-positive cells (Fig. 2B), showing that H-ras was active in both control and CCM3-deficient cells. However, it did not inhibit DNA synthesis (Fig. 2C), nor did it induce a senescent morphology or senescence-associated β-galactosidase activity (Fig. 2D). Moreover, depletion of CCM3 with completely unrelated shRNAs transduced by retroviral vectors had the same effect (Fig. S2, Supporting information), showing again that it is CCM3 downregulation and not a nonspecific effect of CCM3 shRNAs what induces the senescence bypass.

© 2015 The Authors. Aging Cell published by the Anatomical Society and John Wiley & Sons Ltd.
Once we concluded that CCM3 depletion inhibited senescence in several different models, we wanted to understand how CCM3 could affect senescence in our original endothelial cells. Thus, we performed a transcriptomic analysis comparing expression of genes regulated in senescence in control cells (‘senescence genes’) between passage 12 shNT and shCCM3 cells (Fig. S4A, Supporting information). Gene set enrichment analysis of this comparison against KEGG datasets showed that two sets related to senescence were downregulated in shCCM3 cells: cytokine–cytokine receptor interaction and lysosome (Fig. S4B, Supporting information). Indeed, expression of IL-6 and IL-8 mRNAs was lower in late passage CCM3-depleted cells than in control cells as assessed by quantitative RT–PCR (Fig. 3A). Also, while late passage control cells secreted high quantities of IL-6, IL-8, and TGF-β2 to their medium, cells without CCM3 did not (Fig. 3B). Interestingly, control cells at high passage had a higher activity of caspase-1 than shCCM3 cells (Fig. 3C), suggesting that the inflammasome is activated differently depending on the CCM3 status, which might affect cytokine response to inflammation-related stimuli.

Regulation of cytokines during senescence depends on a network of positive feedback loops whereby some cytokines stimulate their own expression or that of related molecules (Acosta et al., 2008; Kuilman et al., 2008; Acosta et al., 2013). To assess the regulation of cytokine expression by CCM3, we studied the response of cells to TNF, which is known to regulate IL-6 and IL-8 in endothelial cells. TNF could induce both IL-6 and IL-8 mRNA levels in a time-dependent manner in control cells, and this response was clearly impaired in CCM3-deficient cells (Fig. 4A). The same was true for IL-8 intracellular protein levels and extracellular secretion (Fig. 4B,C). Furthermore, TNF could induce the nuclear translocation of the transcriptional cytokine regulator Nrf2 and increase the mRNA levels of the other principal regulator, C/EBPβ. In the absence of CCM3, the nuclear translocation of Nrf2 was unaffected while the increase in C/EBPβ mRNA was impaired (Fig. 4D,E). This defect in cytokine regulation was not limited to the response to TNF. Treatment with recombinant IL-8 induced the mRNAs of IL-6 and IL-8 in control but not CCM3-deficient cells, and this was also accompanied by an impaired induction of C/EBPβ in the latter (Fig. 4F). We concluded that the
regulatory network of cytokine regulation was impaired in CCM3-deficient cells, and this was closely related to their inability to induce the C/EBPb transcriptional regulator. C/EBPb was also induced in late passage (senescent) control cells but not in CCM3-deficient cells (Fig. 5A). Moreover, when the expression of C/EBPb was enforced in late passage shCCM3 HCAEC cells, a significant percentage of them accumulated SA-βGal activity and acquired a senescent-like morphology (Fig. 5B), suggesting that CCM3 facilitates senescence at least in part through its effects on C/EBPb expression. Recently, the combination of autophagy and mTOR activity in a newly defined cellular compartment called TOR-autophagy spatial coupling compartment (TASCC), where lysosomes and mTOR accumulate, has been proposed to be essential for cytokine secretion during senescence.

The lysosome gene set is also downregulated in late passage shCCM3 cells, and CCM3 has been implicated in Golgi biogenesis, vesicular trafficking, and regulated secretion (Fidalgo et al., 2010; Kean et al., 2011; Zhang et al., 2013). Thus, we hypothesized that formation of TASCC might be altered in CCM3-deficient cells. As expected, senescent control cells displayed a prominent protein degradation machinery as seen by LAMP2 and p62 staining together with high levels of mTOR, suggestive of the existence of the TASCC complex. On the contrary, cells without CCM3 did not show any signs of TASCC (Fig. 6A). TOR-autophagy spatial coupling compartment is formed by the accumulation of mTOR and lysosomes that result from the high autophagic activity of senescent cells (Narita et al., 2011). As CCM3 is involved in vesicular traffic, we reasoned that it might have an effect on autophagy. Thus, we monitored autophagy in early and late passage...
CCM3-deficient endothelial cells, as assessed by the accumulation of LC3B-II (Fig. 6C). Further, enforced induc- tion of autophagy transiently induced C/EBPb (PD7) or 12 (PD12) by qRT-PCR or Western blot. n = 4, *P = 0.029 vs. shNT. (B) Rescue of C/EBPb induces senescence in late passage shCCM3 HCAEC cells. Lower panel, left: Western blot of C/EBPb in shNT and shCCM3 cells transduced with pLOC or pLOC-C/EBPb at population doublings 18. Upper panels: Microphotographs showing SA-βGal activity in HCAEC shNT cells at population doublings 18, and shCCM3 HCAEC cells transduced with pLOC or pLOC-C/EBPb. Lower panel, right: quantification of SA-βGal-positive cells (mean ± SEM), n = 3. *P = 2.4 x 10^-6. #P = 0.033.

Discussion

We show here that CCM3 is important for senescence in primary cells and propose that the link between CCM3 and senescence is its involvement in autophagy and TASCC formation, which are essential for the induction of the transcription factor C/EBPb and the production of senescence-associated cytokines. These results shed new light in the actions of CCM3 at the cellular level and into the relations between autophagy, C/EBPb, and senescence.

CCM3 is involved in autophagy, not only during senescence but also after nutrient deprivation in postsenescent cells. As CCM3 is important for certain aspects of membrane handling in the cell, such as Golgi biogenesis and regulated secretion, we expect it to be involved in the early stages of autophagosome formation. In fact, the ability of CCM3 to bind to phosphatidylinositolos on one end and kinases of the GCKIII family on the other (Sugden et al., 2013; Zalvide et al., 2013), and its action modulating the binding of the STK24 kinase to the secretory regulator UNC13D (Zhang et al., 2013), may be important for its autophagy promoting function.

CCM3 is also important in the induction of the transcriptional regulator C/EBPb, both during senescence and in response to cytokines, two responses that may be related given the importance of cytokine–cytokine networks in the senescence process. The experiments also suggest that C/EBPb expression depends upon autophagy induction, at least in some settings. Because C/EBPb can also stimulate autophagy, as has also been found in other systems (Ma et al., 2011; Guo et al., 2013), we propose there is a positive feedback loop between this transcription factor and autophagy during senescence. C/EBPb has been proposed to contribute to the cell cycle arrest in senescence by inducing the expression of cdk inhibitors such as p15ink4b in models where this is the principal inhibitor induced (Kuilman et al., 2008). Also, the senescence-associated secretion has been shown to induce many of the features of senescence in a paracrine manner (Acosta et al., 2013). Thus, we hypothesize that lack of C/EBPb expression underlies the lack of induction of senescence markers in CCM3 silenced cells and their inability to growth arrest. This is supported by the rescue of the senescence phenotype by enforced expression of C/EBPb.

Our results add to our knowledge of cellular functions of CCM3, which has been implicated in cell death and in regulation of cell proliferation. CCM3 overexpression has been shown to induce apoptosis, and its inhibition to protect from necrosis after oxidative stress; and from apoptosis after serum deprivation, cycloheximide treatment, or...
depletion of γ-protocadherins (Chen et al., 2009; Lin et al., 2010; Louvi et al., 2011; Fidalgo et al., 2012). We have not challenged our cells with death inducing factors so that we do not observe cell death which CCM3 might inhibit, either by sub-2n DNA or nuclear morphology. Thus, we propose that the senescent effect of CCM3 is independent of its apoptosis regulating functions. We also do not see an effect on proliferation in early passage endothelial cells. This is consistent with the results reported for HuVEC cells, in which a marginal effect or no effect at all of CCM3 depletion on proliferation is seen (Schleider et al., 2010; Zhu et al., 2010), and opposed to the clear effect of CCM3 inhibition on proliferation in astrocytes (Louvi et al., 2011).

Patients with a heterozygous mutation of CCM3 have a high susceptibility to develop cerebral cavernous malformations, and it has been shown recently that they can also develop meningiomas, which places CCM3 as a possible tumor suppressor gene (Clark et al., 2013; Riant et al., 2013). Despite intensive research in the last years, the mechanism by which lack of CCM3 (or lack of CCM1 or CCM2) in endothelial cells results in cavernous malformations is still the subject of debate. Defects in cellular death, polarization, migration, adhesion, and also in endothelial barrier functions, angiogenesis, and differentiation have all been proposed as contributing to cavernoma development (for a review, see Fischer et al., 2013). Our results add a new defect of endothelial cells lacking a CCM gene, the inability to enter senescence. While endothelial cell senescence is usually related to aging, senescent cells can develop prematurely as a consequence of cell stress, and new evidence suggests that senescence may also be a developmentally regulated process that contributes to the disposal of surplus cells (Munoz-Espin et al., 2013; Storer et al., 2013). Experiments designed to analyze whether senescent endothelial cells appear in the brain under specific circumstances, such as angiogenesis, are needed to further study the possible relation between senescence and the development of cavernous malformations.

Mutations of the CCM3 gene can also result in multiple meningiomas, and the ability of CCM3 to induce senescence is likely to contribute to their development. This opens a new avenue of research on the relation between CCM3, senescence, and meningioma development.

---

**Fig. 6** CCM3 is important for autophagy induction during senescence. (A) TOR-autophagy spatial coupling compartment (TASCC) markers in control (shNT) and shCCM3 HCAEC cells as seen by immunofluorescence. Upper photographs show the costaining of p62/SQSTM1 and mTOR. Medium photographs show the costaining of the lysosomal marker LAMP2 and mTOR. Lower photographs show the staining of the trans-Golgi marker TGN46 and the lysosomal marker LAMP2. The bar represents 20 μm. (B) Western blot for LC3B in shNT and shCCM3 HCAEC cells at population doubling 7 and 18. Where indicated, cells were treated with autophagy inhibitor bafilomycin 100 nM for 1 h. LC3B-II levels were determined by fluorescent Western blot. Tubulin is shown as a loading control. Right panel: autophagic flux under each condition. (C) C/EBPβ expression induces autophagy in late passage CCM3-deficient cells. Western blot of LC3B-II in HCAEC cells transduced with pLOC or pLOC-C/EBPβ. (D) Induction of autophagy by mTOR inhibition upregulates IL-6, IL-8, and C/EBPβ levels in endothelial cells deficient for CCM3. Cells were treated with Torin1 for 4 h and incubated with bafilomycin 1 for the last hour where indicated. Accumulation of LC3B-II was quantified by Western blot. Levels of IL-6, IL-8, and C/EBPβ mRNAs were then determined by qRT–PCR after treatment with Torin1 250 nM for the indicated hours. n = 3, *P = 0.043, 5 × 10−5, and 0.044 vs. untreated cells.
Experimental procedures

Antibodies and plasmids

The antibodies used in this study were as follows: TGN46 (Abcam; ab16052); CCM3 (Acris; AP26023PU-N); BrdU (BD Biosciences; 555627); Lamp-2 (BD Biosciences; 555803); p21<sup>cip1</sup> (Santa Cruz; sc-6246); p16<sup>ink4a</sup> (BD Biosciences; 511325); p62 (BD Biosciences; 610832); GAPDH (Calbiochem; CB-1001); LC3B (Cell Signaling; 3868); mTOR (Cell Signaling; 2983); HZAX (Ser139) (Millipore; 05-636); IL-8 (500-P28) (PeproTech; 500-P28); Nfkb p65 (Santa Cruz; sc-8008); p53 (DO-1) (Santa Cruz; sc-126); C/EBPβ (Santa Cruz; sc-150); and tubulin (T5168) (Sigma-Aldrich). The secondary antibodies used were as follows: goat anti-rabbit DyLight<sup>TM</sup> 800, goat anti-mouse DyLight<sup>TM</sup> 680 (Thermo Scientific); goat anti-mouse Alexa 488, goat anti-rabbit Alexa 488, goat anti-mouse Alexa 594, and goat anti-rabbit Alexa 546 (Molecular Probes).

All plasmids were constructed using standard molecular biology techniques.

Cell culture

HCAEC cells, hTERT-RPE1, and IMR90 cells were obtained from European Collection of Cell Cultures and were grown as recommended. Replicative senescence was induced in HCAEC cells by passaging them every 2 days in MesoEndo Cell Growth Medium 212-500 (Cell Applications, Inc.). Oncogene-induced senescence was induced in ER: Ras-IMR90 by treatment with hydroxytamoxifen for 5 days. All experiments where population doublings are specified refer to shCCM3 cells of those population doublings or shNT cells cultured in parallel for the same time.

shRNA-mediated knockdown and recovery

Stable cell populations with silenced CCM3 or control were obtained via selection after lentiviral transduction using MISSION lentiviral nontarget shRNA control transduction particles or MISSION lentiviral shRNA transduction particles against human CCM3, from Sigma-Aldrich (TRC), or by retroviral transduction where stated. shRNAs sequences are available upon request. Lentiviral transduction of CCM3 and C/EBPβ was performed using plasmids from the Precision LentiORF Collection (Thermo Scientific Open Biosystems). Transduced cells were then selected by blasticidin.

Treatments

HCAEC cells were treated with doxorubicin (Sigma-Aldrich) 1 μM for 24 h. hTERT-RPE1 cells were treated HBSS (Invitrogen) for 4 h to trigger autophagy. In the last hour, cells were treated with bafilomycin A1 (Calbiochem) 0.1 μM, or left untreated. HCAEC cells were grown in the presence of recombinant human IL-8 or TNF (R & D Systems) 200 ng μL<sup>-1</sup>. mTOR activity was inhibited with Torin1 (Tocris) 250 nM. IMR90 cells were treated with 4-hydroxytamoxifen (Sigma-Aldrich) 200 nM to activate Ras in IMR90 Ras:ER.

Immunofluorescence and image analysis

HCAEC and hTERT-RPE1 cells were fixed, permeabilized, blocked, and incubated with primary antibodies overnight at 4 °C in PBS + 1% BSA. DNA was stained with Hoechst 33342. Confocal images were collected using a Leica confocal microscope equipped with an HCX PL APO CS 63x/1.32 objective. Leica LCS software was used for acquisition and analysis. Images are combinations of optical sections taken in the z-axis at 0.13-μm intervals. Immunofluorescences in IMR90 cells were analyzed using the high-throughput InCell Analyzer 1000 (GE Healthcare) following manufacturer’s instructions.

Western blot analysis

Western blotting was performed by standard procedures. Signals were quantified with Li-COR Odyssey software.

Senescence-associated β-galactosidase assay

Cells were fixed and stained for SA-βGal by standard protocols. Quantification was performed by two independent observers.

Quantitative RT–PCR

Primers for TaqMan analysis were from Roche Diagnostics: Samples were normalized to ACTB and RPLP0. Primers for TaqMan analysis were from Roche Diagnostics: ACTB (101125), C/EBPβ (100269), IL-6 (113614), IL-8 (103136), LC3B (144005), and RPLP0 (101144).

ELISAs and conditioned media

ELISA kits to detect IL-6, IL-8, and TGF-β2 were from Gen-Probe Diacclone. CM was prepared by washing with serum-free DMEM and incubating in serum-free DMEM for 24 h. All ELISA data were normalized to cell number.

Caspase-1 activity

Caspase-1 activity was measured with a caspase-1 fluorometric assay kit (R & D systems) following manufacturer’s instructions.

Flow cytometry

Cell cycle distribution experiments were performed using a FACScan flow cytometer (Becton & Dickinson, San Jose, CA, USA) and analyzed using FLOWJO software.

Microarrays

RNA extracts from HCAEC cells were obtained using Trizol<sup>®</sup> reagent (Life Technologies) and quantified with a NanoDrop 2000 (Thermo Scientific). RNA quality was assessed using a RNA 6000 Nano Kit (Agilent Biotechnologies). Microarrays were prepared using the following kits: Ambion<sup>®</sup> WT Expression Kit (Life Technologies) and Human GeneChip<sup>®</sup> Whole Transcript Terminal Labeling Expression Kit (Affymetrix). RNAs were hybridized to GeneChip Human Gene 1.0 ST Arrays. Genes differentially expressed between shNT p7 and p12 cells (senescence genes) were ranked according to their relative expression between shCCM3 and shNT p12 cells and used for gene set enrichment analysis (Subramanian et al., 2005) against gene sets from KEGG pathways. The microarray data from this publication have been submitted to the Gene Expression Omnibus Data Repository and assigned the identifier GSE54095.
Statistical analysis

The statistical significance of all data obtained was assessed by Student's t-tests, or ANOVA testing followed by Bonferroni correction where several comparisons were made, using SPS software version 12.0.0. All experiments where statistical significance is shown were repeated a minimum of three times.

Acknowledgments

This work was supported by Xunta de Galicia grant INCITE 09 208 110 PR GCP2013-032 (to C. M. P.), and Ministerio de Ciencia e Innovación grant SAF2011-24940 (to J. Z.), cofinanced with Regional Development European Funds, and ERANET neuron PRI-PIMINEU-2011-1337. A. G. was recipient of an FPU predottorship from Ministerio de Ciencia e Innovación, Spain. C. I. and E. F. are recipients of a predottorship from Xunta de Galicia, Spain.

Funding

No funding information provided.

Conflict of interest

The authors declare no conflict of interest.

Author contributions

A. G. designed experiments, performed most of the experiments, helped to analyze and discuss the results, and wrote the manuscript. C. I., E. F., and M. T. performed some experiments, helped A. G. with some of their experiments, and took part in discussions and analysis of results. S. R. helped A. G. with performing and analyzing the experiments on human fibroblasts. J. G. and C. P. designed some of the experiments, analyzed and discussed the results, and helped to write the manuscript. J. Z. began the project, designed experiments, analyzed the results, and wrote the manuscript.

References

Ccm3 in senescence, A. Guerrero et al.


Supporting Information

Additional Supporting Information may be found in the online version of this article at the publisher’s web-site.

**Fig. S1** Phenotype of late passage CCM3 deficient endothelial cells.

**Fig. S2** CCM3 depletion with unrelated shRNAs bypasses OIS in IMR90 cells.

**Fig. S3** C/EBPβ but not CCM3 mRNA levels are downregulated in spontaneous meningiomas.

**Fig. S4** Transcriptome analysis shows lack of induction of cytokine and lysosome genes in late passage CCM3 depleted cells.

**Fig. S5** CCM3 role in autophagy is independent of senescence.

**Table S1.** Senescence genes downregulated in the absence of CCM3.